FDA Makes End of Zepbound, Mounjaro Shortage Official

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded versions.

“While the drugs faced shortages, direct-to-consumer operators stepped in, taking advantage of rules that allow compounding pharmacies to make medicines with supply issues. Now that the shortage for Lilly is over, the FDA on Wednesday warned that facilities can’t make compounded drugs that simply copy agency-approved ones.”

Continue reading FDA Makes End of Zepbound, Mounjaro Shortage Official